Literature DB >> 22076835

The endocannabinoid system: role in energy regulation.

Thomas F Gamage1, Aron H Lichtman.   

Abstract

Cannabis sativa has been used since antiquity to treat many ailments, including eating disorders. The primary psychoactive constituent of this plant, Δ(9) -tetrahydrocannabinol (THC) is an FDA approved medication to treat nausea and emesis caused by cancer chemotherapeutic agents as well as to stimulate appetite in AIDS patients suffering from cachexia. The effects of THC are mediated through the endocannabinoid system (ECS), which promotes a positive energy balance through stimulation of appetite as well as shifting homeostatic mechanisms toward energy storage. Here we discuss the physiological function of the ECS in energy balance and the therapeutic potential of targeting this system.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22076835      PMCID： PMC3696506          DOI： 10.1002/pbc.23367

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN： 1545-5009            Impact factor:   3.167


  79 in total

Review 1.  Endocannabinoid biosynthesis and inactivation, from simple to complex.

Authors:  Giulio G Muccioli
Journal:  Drug Discov Today       Date:  2010-03-19       Impact factor: 7.851

Review 2.  The endocannabinoid system as a link between homoeostatic and hedonic pathways involved in energy balance regulation.

Authors:  V Di Marzo; A Ligresti; L Cristino
Journal:  Int J Obes (Lond)       Date:  2009-06       Impact factor: 5.095

3.  Characterization of mice lacking candidate N-acyl ethanolamine biosynthetic enzymes provides evidence for multiple pathways that contribute to endocannabinoid production in vivo.

Authors:  Gabriel M Simon; Benjamin F Cravatt
Journal:  Mol Biosyst       Date:  2010-04-14

4.  Loss of retrograde endocannabinoid signaling and reduced adult neurogenesis in diacylglycerol lipase knock-out mice.

Authors:  Ying Gao; Dmitry V Vasilyev; Maria Beatriz Goncalves; Fiona V Howell; Carl Hobbs; Melina Reisenberg; Ru Shen; Mei-Yi Zhang; Brian W Strassle; Peimin Lu; Lilly Mark; Michael J Piesla; Kangwen Deng; Evguenia V Kouranova; Robert H Ring; Garth T Whiteside; Brian Bates; Frank S Walsh; Gareth Williams; Menelas N Pangalos; Tarek A Samad; Patrick Doherty
Journal:  J Neurosci       Date:  2010-02-10       Impact factor: 6.167

5.  Central and peripheral consequences of the chronic blockade of CB1 cannabinoid receptor with rimonabant or taranabant.

Authors:  Elena Martín-García; Aurelijus Burokas; Miquel Martín; Fernando Berrendero; Blanca Rubí; Christoph Kiesselbach; Andrea Heyne; Juan Domingo Gispert; Olga Millán; Rafael Maldonado
Journal:  J Neurochem       Date:  2009-12-17       Impact factor: 5.372

6.  The serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid receptors.

Authors:  William R Marrs; Jacqueline L Blankman; Eric A Horne; Aurore Thomazeau; Yi Hsing Lin; Jonathan Coy; Agnes L Bodor; Giulio G Muccioli; Sherry Shu-Jung Hu; Grace Woodruff; Susan Fung; Mathieu Lafourcade; Jessica P Alexander; Jonathan Z Long; Weiwei Li; Cong Xu; Thomas Möller; Ken Mackie; Olivier J Manzoni; Benjamin F Cravatt; Nephi Stella
Journal:  Nat Neurosci       Date:  2010-07-25       Impact factor: 24.884

7.  Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity.

Authors:  Joseph Tam; V Kiran Vemuri; Jie Liu; Sándor Bátkai; Bani Mukhopadhyay; Grzegorz Godlewski; Douglas Osei-Hyiaman; Shinobu Ohnuma; Suresh V Ambudkar; James Pickel; Alexandros Makriyannis; George Kunos
Journal:  J Clin Invest       Date:  2010-07-26       Impact factor: 14.808

8.  Diacylglycerol lipase is not involved in depolarization-induced suppression of inhibition at unitary inhibitory connections in mouse hippocampus.

Authors:  Rogier Min; Guilherme Testa-Silva; Tim S Heistek; Cathrin B Canto; Johannes C Lodder; Tiziana Bisogno; Vincenzo Di Marzo; Arjen B Brussaard; Nail Burnashev; Huibert D Mansvelder
Journal:  J Neurosci       Date:  2010-02-17       Impact factor: 6.167

9.  Endocannabinoids selectively enhance sweet taste.

Authors:  Ryusuke Yoshida; Tadahiro Ohkuri; Masafumi Jyotaki; Toshiaki Yasuo; Nao Horio; Keiko Yasumatsu; Keisuke Sanematsu; Noriatsu Shigemura; Tsuneyuki Yamamoto; Robert F Margolskee; Yuzo Ninomiya
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-22       Impact factor: 11.205

10.  Cannabinoid in the nucleus accumbens enhances the intake of palatable solution.

Authors:  Yuhei Shinohara; Tadashi Inui; Takashi Yamamoto; Tsuyoshi Shimura
Journal:  Neuroreport       Date:  2009-10-07       Impact factor: 1.837
View more
  7 in total

1.  Systems biology analysis of the endocannabinoid system reveals a scale-free network with distinct roles for anandamide and 2-arachidonoylglycerol.

Authors:  Nicola Bernabò; Barbara Barboni; Mauro Maccarrone
Journal:  OMICS       Date:  2013-10-11

2.  Two fatty acid-binding proteins expressed in the intestine interact differently with endocannabinoids.

Authors:  May Poh Lai; Francine S Katz; Cédric Bernard; Judith Storch; Ruth E Stark
Journal:  Protein Sci       Date:  2020-04-28       Impact factor: 6.725

Review 3.  From passive overeating to "food addiction": a spectrum of compulsion and severity.

Authors:  Caroline Davis
Journal:  ISRN Obes       Date:  2013-05-15

Review 4.  The biological networks in studying cell signal transduction complexity: The examples of sperm capacitation and of endocannabinoid system.

Authors:  Nicola Bernabò; Barbara Barboni; Mauro Maccarrone
Journal:  Comput Struct Biotechnol J       Date:  2014-09-06       Impact factor: 7.271

Review 5.  Targeting cancer cachexia: Molecular mechanisms and clinical study.

Authors:  Yong-Fei Wang; Zi-Yi An; Dong-Hai Lin; Wei-Lin Jin
Journal:  MedComm (2020)       Date:  2022-09-10

6.  New role of phenothiazine derivatives as peripherally acting CB1 receptor antagonizing anti-obesity agents.

Authors:  Mayank Kumar Sharma; Jatin Machhi; Prashant Murumkar; Mange Ram Yadav
Journal:  Sci Rep       Date:  2018-01-26       Impact factor: 4.379

Review 7.  Targeting the Endocannabinoid CB1 Receptor to Treat Body Weight Disorders: A Preclinical and Clinical Review of the Therapeutic Potential of Past and Present CB1 Drugs.

Authors:  Thomas Murphy; Bernard Le Foll
Journal:  Biomolecules       Date:  2020-06-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.